Background & aim: The long-acting glucagon-like peptide-1 (GLP-1) analogue semaglutide is approved for the treatment of type 2 diabetes and obesity. Recently, semaglutide has been reported to improve liver histopathological outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis…
Background & aim: OPK-88006 is a novel peptide-based, long-acting glucagon-like peptide-1 receptor (GLP1R)/glucagon receptor (GCGR) dual agonist in current preclinical development for metabolic diseases, including obesity and metabolic dysfunction-associated steatohepatitis (MASH). The present study aimed to compare the therapeutic profile…
Background & aim: The glucagon-like peptide-1 receptor (GLP1R) and gastric inhibitory polypeptide receptor (GIPR) dual agonist tirzepatide is currently approved for the treatment of obesity and type 2 diabetes. In a recent phase 2b trial (SYNERGY-NASH) in patients with metabolic-dysfunction…
Background & aim: Survodutide is a dual agonist of the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R), currently in clinical development for obesity and related metabolic disorders. By concurrently enhancing GCGR and GLP1R signaling, survodutide offers a synergistic approach…
Aim: Utilize orexin analogues to activate central orexin signaling and compensate for the loss of endogenous orexin function in Narcolepsy Type 1 (NT1). How? Engineering highly potent dual orexin receptor (OxR) 1 and OxR2 agonists from orexin backbone with optimized…
Background & aim: Injectable peptide-based GLP-1 receptor agonists (GLP1RAs) are effective treatments for obesity and type 2 diabetes, yet present challenges related to patient compliance and scalable production. In contrast, small-molecule GLP1RAs offer significant advantages, including oral bioavailability and scalable…
Background & aim: Cellular-level insights into metabolic associated steatohepatitis (MASH) and its progression to hepatocellular carcinoma (HCC) have been limited by bulk RNA-sequencing, which masks rare or tumor-relevant populations. Here, we applied single-cell transcriptomics to characterize liver cell-specific transcriptome changes…
Background & aim: Growing evidence suggests that senescent cells contribute to the development and progression of idiopathic pulmonary fibrosis (IPF). This study aimed to identify and characterize key markers of lung senescence using a repetitive bleomycin-induced (BLEO), spirometry-confirmed mouse model…
Background & aim: Clinically derived Ashcroft scoring of lung fibrosis is commonly applied to preclinical models of idiopathic pulmonary fibrosis (IPF). As for any manual, semiquantitative histopathological scoring system, Ashcroft scoring is prone to inter- and intra-observer variability which influences…
